FrancophonIA/ELRC3.0 huggingface dataset:
English: Vantavo must not be used in patients who have abnormalities of the oesophagus, who have hypocalcaemia (low blood calcium levels), or who cannot stand or sit upright for at least 30 minutes.
Maltese: Vantavo m'għandux jintuża minn pazjenti li jkollhom anomaliji fl-esofagu, li jkollhom ipokalċemija (livelli baxxi ta' kalċju fid-demm), jew li ma jkunux jistgħu jqumu bilwieqfa jew ipoġġu dritti għal millanqas 30 minuta.
English: Vantavo (containing either 2,800 or 5,600 IU colecalciferol) is used to treat osteoporosis (a disease that makes bones fragile) in women who have been through the menopause and are at risk of low vitamin D levels.
Maltese: Vantavo (li fih 2,800 jew 5,600 IU colecalciferol) jintuża fit-trattament tal-osteoporożi (marda li tagħmel l-għadam fraġli) fin-nisa wara l-menopawża u li jkunu f'riskju ta' livelli baxxi ta' vitamina D. Vantavo 70 mg/5,600 IU jintuża f'pazjenti li mhumiex qegħdin jieħdu supplementi tal-vitamina D. Vantavo jnaqqas ir-riskju ta' ksur tal-għadam fis-sinsla tad-dahar u fil-ġenbejn.
English: The additional studies showed that including vitamin D3 in the same tablet with alendronic acid could increase vitamin D levels.
Maltese: L-istudji addizzjonali wrew li meta jkun hemm il-vitamina D3 fl-istess pillola mal-aċidu alendroniku, dan jista' jżid il-livelli tal-vitamina D.
English: A risk management plan has been developed to ensure that Vantavo is used as safely as possible.
Maltese: Ġie żviluppat pjan ta' ġestjoni tar-riskju biex jiġi żgurat li Vantavo jintuża bl-aktar mod sigur possibbli.
English: EU Number Invented
Maltese: Numru tal-proċedura ta' l-EMEA
English: Strength Pharmaceutical
Maltese: Perjodu ta' Tiżmim
English: adults.
Maltese: adulti.
English: Ref. EMEA/519568/2007
Maltese: EMEA/519568/2007
English: London, 15 November 2007 Doc.
Maltese: Londra, 15 ta' Novembru 2007 Dok. Ref.
English: 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 75 23 71 29 E-mail: mail@emea.europa.eu http://www.emea.europa.eu©EMEA 2007 Reproduction and/or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged
Maltese: (44-20) 74 18 84 00 Fax (44-20) 75 23 71 29 E-mail: mail@emea.europa.eu http://www.emea.europa.eu©EMEA 2008 Reproduction and/or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged
English: International non-proprietary name (INN): 1-13C-caprylic acid
Maltese: Denominazzjoni Komuni Internazzjonali (INN): 1-13C-caprylic acid
English: Gastromotal is a diagnostic test.
Maltese: Gastromotal huwa test dijanjostiku.
English: The active substance in Gastromotal, 1-13C-caprylic acid, is a natural chemical called caprylic acid that has been labelled with carbon-13 (13C).
Maltese: Is-sustanza attiva f'Gastromotal, 1-13C-caprylic acid, hija kimika naturali magħrufa bħala caprylic acid li tkun ġiet ittikkettjata bil-karbonju-13 (13C).
English: The CHMP normally takes up to 210 days to evaluate a new application.
Maltese: Is-CHMP normalment idum sa 210t ijiem biex jivvaluta applikazzjoni ġdida.
English: It was to be available as a syringe containing a liquid for drinking, containing the active substance 1-13C-caprylic acid (90 mg).
Maltese: Kellu jiġi bħala siringa li fiha likwidu għax-xorb, li fih is-sustanza attiva 1-13C-caprylic acid (90 mg).
English: What is Gastromotal?
Maltese: X'inhu Gastromotal?
English: This labelled carbon dioxide can be detected in breath samples taken every 15 to 30 minutes in the four hours after the test meal.
Maltese: Dan id-diossidu tal-karbonju ttikkettjat jista' jinqabad f'kampjuni tan-nifs meħudin bejn kull 15 u 30 minuta fl-erba' sigħat ta' wara l-ikla tat-test.
English: This means that it contains 13C, a non-radioactive, rare form of the carbon atom, instead of carbon-12 (12C), the form that is the most common in nature.
Maltese: Dan ifisser li fiha 13C, forma rari, mhux radjuattiva ta' latomu tal-karbonju, minflok il-karbonju-12 (12C), il-forma li hija l-iktar komuni fin-natura.
English: The effectiveness of Gastromotal has been compared with that of a standard test called 99Tc-scintigraphy (a type of scan using radioactive tracers) in two main studies involving a total of 310
Maltese: L-effikaċja ta' Gastromotal tqabblet ma' dik ta' test standard magħruf bħala 99Tc-scintigraphy (tip ta' skenn li juża t-traċċaturi radjuattivi) f'żewġ studji ewlenin bis-sehem ta' 310
English: Once the company has supplied responses to the questions, the CHMP reviews them and may, before giving an opinion, ask any remaining questions at day 180.
Maltese: qabel ma jagħti l-opinjoni, jistaqsi xi mistoqsijiet oħra fil-180 jum.
English: In the main studies, the level of agreement between Gastromotal and the standard test was too low to be acceptable, resulting in a considerable risk of false positive and false negative results.
Maltese: Fl-istudji ewlenin, il-livell ta' qbil bejn Gastromotal u t-test standard kien baxx wisq biex ikun aċċetabbli, u dan kien iwassal għal riskju konsiderevoli ta' riżultati falsament pożittivi u falsament negattivi.
English: On 5 November 2007, INFAI, Institut für biomedizinische Analytik & NMR-Imaging GmbH officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Gastromotal, for in vivo diagnosis of solidphase gastric half emptying time in gastric motility disorders.
Maltese: NMR-Imaging GmbH għarrfu uffiċjalment lill-Kumitat għall-Prodotti Mediċinali għall-Użu mill-Bniedem (CHMP) li jixtiequ jirtiraw l-applikazzjoni tagħhom għal awtorizzazzjoni għat-tqegħid fis-suq għal Gastromotal, għad-dijanjożi in vivo tal-ħin tat-tbattil ta' nofs l-istonku fil-fażi solida fil-problemi ta' motilità ta' listonku.
English: What was Gastromotal expected to be used for?
Maltese: Għal xiex kien mistenni li jintuża Gastromotal?
English: Based on the review of the initial documentation, the CHMP prepares a list of questions at day 120, which is sent to the company.
Maltese: Abbażi ta' l-analiżi taddokumentazzjoni inizjali, is-CHMP iħejji lista ta' mistoqsijiet fil-120 jum u dan jintbagħat lillkumpanija.
English: How is Gastromotal expected to work?
Maltese: Kif kien mistenni jaħdem Gastromotal?
English: The effects of Gastromotal were first tested in experimental models before being studied in humans.
Maltese: L-effetti ta' Gastromotal għall-ewwel ġew ittestjati f'mudelli sperimentali qabel ma ġew studjati fuq il-bniedem.
English: Gastromotal was expected to be used to diagnose delayed stomach emptying in patients with stomach problems.
Maltese: Gastromotal kien mistenni li jintuża fid-dijanjożi tad-dewmien fit-tbattil ta' l-istonku f'pazjenti bi problemi ta' l-istonku.
English: D-85540 Haar
Maltese: D-85540
English: 2770-192 Paço de Arcos Portugal
Maltese: 2770-192 Paço de Arcos Il-Portugall
English: 00-867 Warszawa Poland
Maltese: 00-867 Warszawa
English: MSD Polska Sp. z o.o.
Maltese: MSD Polska Sp. z o.o. ul.
English: C/ Josefa Valcárcel, 38 28027 Madrid Spain
Maltese: C/ Josefa Valcárcel, 38 28027 Madrid Spanja
English: Quinta da Fonte Edifício Vasco da Gama, 19 P.O.
Maltese: Quinta da Fonte Edifício Vasco da Gama, 19 P.O. BOX 214
English: 18th Km Athens-Lamia National Road 14671 Nea Erythrea Greece
Maltese: 18th Km Athens-Lamia National Road 14671 Nea Erythrea
English: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A, Viale Shakespeare, 47 00144 Roma
Maltese: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A, Viale Shakespeare, 47 00144
English: Primaxin DR.PD.INJ (250+250mg/Vial (IV)
Maltese: Primaxin DR.PD.INJ (250+250mg/Kunjett (IV)
English: Box 581, 2003 PC Haarlem
Maltese: P.O. Box 581, 2003 PC Haarlem
English: Primaxin DR.PD.INJ (500+500)mg/Vial (IV)
Maltese: Primaxin DR.PD.INJ (500+500)mg/ Kunjett (IV)
English: Merck Sharp & Dohme, UAB, Kęstučio 59/27, LT-08124 Vilnius
Maltese: Merck Sharp & Dohme, UAB, Kęstučio 59/27, LT-08124
English: Hertford Road, Hoddesdon, Hertfordshire EN11 9BU United Kingdom
Maltese: Hertford Road, Hoddesdon, Hertfordshire EN11 9BU Ir-Renju Unit
English: Merck Sharp & Dohme B.V. Chaussée de Waterloo 1135 1180 Bruxelles Belgium
Maltese: Merck Sharp & Dohme B.V. Chaussée de Waterloo 1135 1180 Bruxelles Il-Belġju
English: Merck Sharp & Dohme Limited, Hertford Road, Hoddesdon, Herts, EN11 9BU United Kingdom
Maltese: Merck Sharp & Dohme Limited, Hertford Road, Hoddesdon, Herts, EN11 9BU Ir-Renju Unit
English: 500mg /500mg i.v.
Maltese: Tienam i.v. 500mg /500mg i.v.
English: Am
Maltese: Haar
English: Powder for suspension for parenteral use (IM)
Maltese: Trab għal suspensjoni għal użu parenterali (IM)
English: ul.
Maltese: L-Isvezja
English: PrimaxinIV 500mg Injection 500mg
Maltese: Injezzjoni ta' PrimaxinIV 500mg
English: Primaxin IV 500mg Injection 500mg
Maltese: Injezzjoni ta' Primaxin IV 500mg
English: Slovak Republic
Maltese: Is- Slovakkja
English: Merck Sharp & Dohme B.V. Waarderweg 39, Haarlem, P.O.Box 581, 2003 PC Haarlem The Netherlands
Maltese: Merck Sharp & Dohme B.V. Waarderweg 39, Haarlem, P.O.Box 581, 2003 PC Haarlem L-Olanda
English: Šmartinska cesta 140, 1000 Ljubljana, Slovenia
Maltese: Merck Sharp & Dohme, inovativna zdravila d.o.o. Šmartinska cesta 140, 1000 Ljubljana, Slovenja
English: Merck Sharp & Dohme B.V. Waarderweg 39, 2031 BN Haarlem, The Netherlands
Maltese: Merck Sharp & Dohme B.V. Waarderweg 39, 2031 BN Haarlem, L-Olanda
English: Euro Platz 2 1120 Wien Austria
Maltese: Am Euro Platz 2
English: Bulgaria
Maltese: Il-Bulgarjia
English: 250 mg/250 mg Powder for infusion
Maltese: 250 mg/250 mg Trab għall-infużjoni
English: 500 mg powder for solution for infusion 500 mg/500 mg Powder for solution for infusion Intravenous use
Maltese: Pulver zur Herstellung einer Infusionslösung 500 mg/500 mg
English: TIENAM 500 mg/500 mg, poudre pour perfusion 500 mg/500 mg Powder for infusion
Maltese: TIENAM 500 mg/500 mg, poudre pour perfusion
English: List of the names, pharmaceutical forms, strengths of the medicinal products, routes of administration, marketing authorisation holders in the Member States
Maltese: Lista tal-ismijiet, għamliet farmaċewtiċi, qawwiet tal-prodotti mediċinali, mnejn jingħataw, id-detenturi tal-awtorizzazzjoni għat-tqegħid fis-suq flIstati Membri
English: 500 mg + 500 mg Powder for solution for injection Intravenous use
Maltese: 500 mg + 500 mg Trab għal soluzzjoni għallinjezzjoni
English: Merck Sharp & Dohme OÜ Peterburi St 46, 11415 Tallinn
Maltese: Merck Sharp & Dohme OÜ Peterburi
English: Further information on Keytruda can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/keytruda.
Maltese: Aktar informazzjoni dwar Keytruda tinstab fis-sit web tal-Aġenzija: ema.europa.eu/medicines/human/EPAR/aflunov.
English: Other information about Keytruda
Maltese: Informazzjoni oħra dwar Keytruda
English: • melanoma, a skin cancer,
Maltese: • melanoma, kanċer tal-ġilda,
English: Keytruda received a marketing authorisation valid throughout the EU on 17 July 2015.
Maltese: Keytruda rċieva awtorizzazzjoni għat-tqegħid fis-suq valida fl-UE kollha fis-17 ta' Lulju 2015.
English: Hodgkin lymphoma
Maltese: Linfoma ta' Hodgkin
English: At 18 months, 81% of the patients given the combination were alive, compared with 71% in the sunitinib group.
Maltese: Wara 18 xahar, 81 % tal-pazjenti li ngħataw il-kombinazzjoni kienu ħajjin meta mqabbla ma' 71 % fil-grupp tas-sunitinib.
English: Keytruda contains the active substance pembrolizumab.
Maltese: Keytruda fih is-sustanza attiva pembroliżumab.
English: Non-small cell lung cancer (NSCLC)
Maltese: Kanċer tal-pulmun b'ċelloli mhux żgħar (NSCLC)
English: Keytruda is given as an infusion (drip) into a vein.
Maltese: Keytruda jingħata bħala infużjoni (dripp) ġo vina.
English: What are the risks associated with Keytruda?
Maltese: X'inhuma r-riskji assoċjati ma' Keytruda?
English: The active substance in Keytruda, pembrolizumab, is a monoclonal antibody, a protein that has been designed to recognise and block a receptor (‘target') called PD-1.
Maltese: Is-sustanza attiva f'Keytruda, il-pembroliżumab, hija antikorp monoklonali, proteina li tfasslet biex tagħraf u timblokka riċettur (“mira”) imsejjaħ PD-1.
English: It can be used on its own or in combination with other cancer medicines for NSCLC and HNSCC.
Maltese: Jista' jintuża waħdu jew flimkien ma' mediċini oħra kontra l-kanċer għal NSCLC u HNSCC.
English: Patients taking the Keytruda combination lived on average for 13.6 months compared with 10.4 months for patients taking other standard treatments.
Maltese: Il-pazjenti li kienu qed jieħdu l-kombinazzjoni ta' Keytruda għexu medja ta' 13.6 xhur meta mqabbla ma' 10.4 xhur għall-pazjenti li kienu qed jieħdu kuri standard oħra.
English: In a further study of 559 patients with ‘squamous' NSCLC that had spread, patients given Keytruda with carboplatin and paclitaxel or nab-paclitaxel lived on average for 15.9 months compared with 11.3 months for patients given placebo with carboplatin and paclitaxel or nab-paclitaxel.
Maltese: Fi studju ieħor fuq 559 pazjent b'NSCLC “skwamuż” li kien infirex, il-pazjenti li ngħataw Keytruda b'carboplatin u paclitaxel jew inkella nab-paclitaxel għexu medja ta' 15.
English: • non-small cell lung cancer (NSCLC), a type of lung cancer,
Maltese: • kanċer tal-pulmun b'ċelloli mhux żgħar (NSCLC), tip ta' kanċer tal-pulmun,
English: After one and a half years of treatment, 72% of patients on Keytruda were still disease-free compared with 54% of patients on placebo.
Maltese: Wara sena u nofs ta' kura, 72 % tal-pazjenti li ngħataw Keytruda kienu għadhom ħielsa mill-mard meta mqabbla ma' 54 % tal-pazjenti fuq plaċebo.
English: In a study of 616 patients with non-squamous NSCLC that had spread, 69% of patients taking Keytruda with pemetrexed and platinum chemotherapy were alive at 11 months, compared with less than half of patients who had only pemetrexed and platinum chemotherapy.
Maltese: Fi studju fuq 616-il pazjent b'NSCLC mhux skwamuż li kien infirex, 69 % tal-pazjenti li kienu qegħdin jieħdu Keytruda b'pemetrexed u bilkimoterapija bil-platinu kienu ħajjin wara 11-il xahar, meta mqabbla ma' inqas minn nofs il-pazjenti li ħadu biss pemetrexed u kimoterapija bil-platinu.
English: Another study in 882 patients with HNSCC showed that Keytruda alone or in combination with platinum and 5-fluorouracil (5-FU) chemotherapy is effective at prolonging patients' lives when HNSCC tests positive for a certain level of PD-L1.
Maltese: Studju ieħor fuq 882 pazjent b'HNSCC wera li Keytruda waħdu jew flimkien ma' kimoterapija bil-platinu u b'5-fluorouracil (5-FU) huwa effettiv biex itawwal il-ħajja tal-pazjenti meta HNSCC jittestja pożittiv għal ċertu livell ta' PD-L1.
English: • classical Hodgkin lymphoma, a cancer of the white blood cells,
Maltese: • linfoma ta' Hodgkin klassika, kanċer taċ-ċelloli tad-demm bojod,
English: A third study in 1,019 patients who had had surgery and who were at high risk for their cancer coming back compared Keytruda to placebo (a dummy treatment).
Maltese: It-tielet studju fuq 1,019-il pazjent li kellhom kirurġija u li kienu f'riskju għoli li l-kanċer tagħhom jerġa' jfeġġ qabbel Keytruda ma' plaċebo (kura finta).
English: In a study of 495 patients, patients treated with Keytruda who had high levels of PD-L1 lived on average for 11.6 months while those taking standard cancer treatments lived for 6.6 months.
Maltese: Fi studju fuq 495 pazjent, il-pazjenti li ġew ikkurati b'Keytruda li kellhom livelli għoljin ta' PD-L1 għexu medja ta' 11.6 xhur meta mqabbla ma' dawk li kienu qegħdin jieħdu kuri tal-kanċer standard li għexu għal 6.6 xhur.
English: Some cancers can make a protein (PD-L1) that combines with PD-1 to switch off the activity of certain cells of the immune system (the body's natural defences) preventing them from attacking the cancer.
Maltese: Xi kanċers jistgħu jagħmlu proteina (PD-L1) li tikkombina mal-PD-1 biex titfi l-attività ta' ċerti ċelloli tas-sistema immunitarja (id-difiżi naturali talġisem) u tipprevjenihom milli jattakkaw il-kanċer.
English: As for all medicines, data on the use of Keytruda are continuously monitored.
Maltese: Bħal fil-każ tal-mediċini kollha, id-data dwar l-użu ta' Keytruda hija ssorveljata kontinwament.
English: • urothelial cancer, a cancer of the bladder and urinary tract,
Maltese: • kanċer uroteljali, kanċer tal-bużżieqa tal-awrina u l-kanal tal-awrina,
English: In a second study of 370 patients who could not be treated with cisplatin-containing medicines, Keytruda produced a complete or partial remission (clearing) of the cancer in 108 patients (29%); a complete remission occurred in 30 (8%) of them, meaning they no longer had any signs of cancer.
Maltese: Fit-tieni studju fuq 370 pazjent li ma setgħux jiġu kkurati b'mediċini li fihom ċisplatin, Keytruda pproduċa remissjoni sħiħa jew parzjali (tneħħija) tal-kanċer f'108 pazjenti (29 %); remissjoni sħiħa seħħet fi 30 (8 %) minnhom, li jfisser li ma kien għad fadlilhom l-ebda sinjal ta' kanċer.
English: Patients treated with Keytruda lived for up to 5.6 months without their disease getting worse compared with 2.8 months with ipilimumab.
Maltese: Il-pazjenti kkurati b'Keytruda għexu sa massimu ta' 5.6 xhur mingħajr ma l-marda tagħhom marret għall-agħar meta mqabbla ma' 2.8 xhur b'ipilimumab.
English: In a study of 861 patients with renal cell carcinoma, patients given Keytruda in combination with an already authorised medicine for renal cell carcinoma, axitinib, lived for around 15 months without their disease getting worse, compared with 11 months for patients who received treatment with another renal cell carcinoma medicine, sunitinib, which was used as a control treatment.
Maltese: Fi studju fuq 861 pazjent b'karċinoma taċ-ċelloli renali, il-pazjenti li ngħataw Keytruda flimkien ma' mediċina li kienet diġà awtorizzata għall-karċinoma taċ-ċelloli renali, axitinib, għexu għal madwar 15-il xahar mingħajr ma l-marda tagħhom marret għall-agħar, meta mqabbla ma' 11-il xahar għal pazjenti li rċevew kura b'mediċina oħra għall-karċinoma taċ-ċelloli renali, sunitinib, li ntużat bħala kura ta' kontroll.
English: The side effects of Keytruda are mostly related to the activity of the immune system, which may cause inflammation of body organs and tissues and can be serious, although most side effects resolve with appropriate treatment or on stopping Keytruda.
Maltese: L-effetti sekondarji ta' Keytruda huma l-aktar relatati mal-attività tas-sistema immunitarja, li tista' tikkawża infjammazzjoni tal-organi u tat-tessuti tal-ġisem u jistgħu jkunu serji, għalkemm ħafna milleffetti sekondarji jissolvew b'kura xierqa jew bit-twaqqif ta' Keytruda.
English: In a main study of 210 patients, Keytruda produced a complete or partial remission (clearing) of the cancer in 145 patients (69%); a complete remission occurred in 47 (22%) of them, meaning they no longer had any signs of cancer.
Maltese: Fi studju ewlieni fuq 210 pazjenti, Keytruda pproduċa remissjoni sħiħa jew parzjali (tneħħija) talkanċer f'145 pazjent (69 %); remissjoni sħiħa seħħet f'47 (22 %) minnhom, li jfisser li ma kien għad fadlilhom l-ebda sinjal ta' kanċer.
English: Keytruda is also effective in preventing melanoma from coming back in patients who have had surgery.
Maltese: Keytruda huwa effettiv ukoll biex jipprevjenti l-melanoma milli tirritorna f'pazjenti li tkun saritilhom kirurġija.
English: For renal cell carcinoma, Keytruda is used in combination with other cancer medicines.
Maltese: Għall-karċinoma taċ-ċelloli renali, Keytruda jintuża flimkien ma' mediċini oħra kontra l-kanċer.
English: A study looked at 542 patients previously treated with platinum-based medicines who received either Keytruda or another cancer medicine chosen by the doctor (paclitaxel, docetaxel or vinflunine).
Maltese: Studju ħares lejn 542 pazjent li qabel kienu ġew ikkurati b'mediċini bbażati fuq il-platinu li rċevew jew Keytruda jew mediċina oħra kontra lkanċer magħżula mit-tabib (paclitaxel, docetaxel jew vinflunine).
English: The company that markets Keytruda will provide patients with an information pack and alert card to inform them about the risks of potential immune-related side effects and give instructions on when to contact their doctor if they experience symptoms.
Maltese: Il-kumpanija li tqiegħed lil Keytruda fis-suq se tipprovdi lill-pazjenti pakkett ta' informazzjoni u kard ta' twissija biex tinfurmahom dwar ir-riskji ta' effetti sekondarji relatati mal-immunità potenzjali u jagħtu struzzjonijiet dwar meta għandhom jikkuntattjaw lit-tabib tagħhom jekk jesperjenzaw sintomi.
English: Keytruda did not delay worsening of the disease compared with the other cancer medicines (time to disease worsening was 2 and 3 months respectively).
Maltese: Keytruda ma ttardjax id-deterjorament tal-marda meta mqabbel mal-mediċini l-oħra kontra l-kanċer (il-ħin li lmarda tieħu biex tmur għall-agħar kien ta' 2 u 3 xhur rispettivament).
English: Keytruda (pembrolizumab)
Maltese: Kanċer tal-ġilda
English: For the full list of side effects and restrictions with Keytruda, see the package leaflet.
Maltese: Għal-lista sħiħa tal-effetti sekondarji u r-restrizzjonijiet b'Keytruda, ara l-fuljett ta' tagħrif.
English: Keytruda is also effective in combination treatment of a type of NSCLC known as ‘non-squamous' cancer, based on the type of cancer cells involved.
Maltese: Keytruda huwa effettiv ukoll fil-kura ta' kombinazzjoni ta' tip ta' NSCLC magħruf bħala kanċer “mhux skwamuż”, ibbażat fuq it-tip ta' ċelloli tal-kanċer involuti.
English: In a second lung cancer study of 305 patients whose tumours tested strongly for PD-L1 who had not been treated before, patients on Keytruda lived for around 10 months without their disease getting worse compared with 6 months in patients receiving platinum-based chemotherapy.
Maltese: Fit-tieni studju tal-kanċer tal-pulmun fuq 305 pazjenti li t-tumuri tagħhom ittestjaw b'mod b'saħħtu għall-PD-L1 li ma kinux ġew ikkurati qabel, il-pazjenti fuq Keytruda għexu għal madwar 10 xhur mingħajr ma l-marda tagħhom marret għall-agħar meta mqabbel ma' 6 xhur f'pazjenti li kienu qegħdin jieħdu kimoterapija bbażata fuq il-platinu.
English: When Keytruda is given alone the dose is either 200 mg every three weeks or 400 mg every six weeks.
Maltese: Meta Keytruda jingħata waħdu d-doża hija jew 200 mg kull tliet ġimgħat jew 400 mg kull sitt ġimgħat.
English: Also, up to 74% of patients treated with Keytruda lived for at least 12 months after the start of their treatment compared with 59% of patients on ipilimumab.
Maltese: Barra minn hekk, sa 74 % talpazjenti li ġew ikkurati b'Keytruda għexu għal tal-anqas 12-il xahar wara l-bidu tal-kura tagħhom meta mqabbla ma' 59 % tal-pazjenti fuq ipilimumab.
English: In some patients, tumours have to produce a high level of PD-L1 for the medicine to be effective.
Maltese: F'xi pazjenti, it-tumuri jkollhom jipproduċu livell għoli ta' PD-L1 biex il-mediċina tkun effettiva.
English: Results from a study of 540 previously treated patients with melanoma showed that 2 years after start of treatment, the disease had not worsened in 16% of patients treated with Keytruda compared with less than 1% of patients treated with chemotherapy.
Maltese: Riżultati minn studju fuq 540 pazjent b'melanoma li ġiet ikkurata qabel urew li sentejn wara l-bidu tal-kura, il-marda ma marritx għall-agħar f'16 % tal-pazjenti kkurati b'Keytruda meta mqabbla ma' inqas minn 1 % talpazjenti kkurati bil-kimoterapija.
English: Keytruda partially or completely clears cancer cells in classical Hodgkin lymphoma that has not improved or had returned after treatment with brentuximab vedotin, with or without an autologous stem cell transplantation.
Maltese: Keytruda huwa effettiv ukoll biex itejjeb is-sopravivenza ta' pazjenti b'karċinoma taċ-ċelloli skwamużi tar-ras u tal-għonq (HNSCC) li tkun infirxet jew irritornat.
English: How is Keytruda used?
Maltese: Kif jintuża Keytruda?
English: Keytruda is a cancer medicine used to treat:
Maltese: Keytruda huwa mediċina kontra l-kanċer li tintuża biex tikkura:
English: A second study looked at 834 patients with melanoma who received either Keytruda or another medicine, ipilimumab.
Maltese: It-tieni studju ħares lejn 834 pazjent b'melanoma li rċevew jew Keytruda jew mediċina oħra, lipilimumab.